



Curetis and Mediphos to Sponsor Expert Discussion on the Future of Infectious Diseases Testing

- *Satellite symposium will be held during the 8th European Meeting on Molecular Diagnostics (EMMD)*
- *Presentation of Curetis' Unyvero™ system by distribution partner Mediphos*

Holzgerlingen, Germany, September 18, 2013 -- Curetis AG today announced it will host the satellite symposium "Molecular microbiology - the future of infectious diseases testing?" together with its Dutch distribution partner Mediphos Medical Supplies during the upcoming 8th European Meeting on Molecular Diagnostics (EMMD). The EMDD will be held from October 2 - 4, 2013, in Scheveningen, The Netherlands.

The symposium, which is scheduled for Oct. 2 from 8:30-10am (Adama Zijlstra Rooms 1 & 2), will be chaired by Prof. Paul Savelkoul (Maastricht University, The Netherlands) and Dr. Anne Thews (Curetis, Germany). Following an overview on the expectations for the future of molecular biology by Prof. Savelkoul, three lectures will discuss challenges and applications: Dr. Eric Claas (LUMC Leiden, the Netherlands) is to talk about "Benefits and challenges of molecular testing in infectious diseases". Dr. Jan Weile (Heart and Diabetes Center Bad Oeynhausen, Germany) will present "First clinical experience with the Unyvero™ P50 Pneumonia Application" and Dr. Anne Thews (Medical Director, Curetis AG) is going to discuss "Implant and tissue infections - a need for multiplexed testing?". The subsequent panel discussion will focus on the question whether fast molecular infectious disease testing will improve patient outcome.

In addition, Mediphos Medical Supplies, the exclusive distribution partner of Curetis for The Netherlands, will present Curetis' Unyvero™ System during the EMMD.

Disclaimer

CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or

transfer any product, and no product based on the Curetis Unyvero™ technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero™ product which may be sold at some future point in time in the U.S. have not yet been established.

###

About the Unyvero™ System

The CE-marked Unyvero™ System is a versatile hardware platform for the detection of a broad panel of bacteria, fungi and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result. It is marketed in Europe, Russia, the Middle East and various other non-European countries. In the U.S., Curetis is running a prospective multi-center clinical trial aimed at achieving FDA clearance registered under www.ClinTrials.gov NCT01922024.

The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure.

Thereby, clinically relevant information is available within about four hours to support an informed therapy decision as early as possible.

The first CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. The second application, the Unyvero™ i60 ITI cartridge for implant & tissue infections, is in late-stage product development. It covers 114 targets from many native clinical sample types and 8 distinct clinical indications. Cartridges for additional indications are in preparation.

About Curetis AG

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised total funds of over € 49.1 million (~ USD 65 million). The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical, Sanofi Pasteur and Cempra Inc. as well as several international distribution agreements covering more than 20 countries already.



Press Release Curetis AG

Contact

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com
www.curetis.com

Media Inquiries

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68